YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer

Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with par...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The EMBO journal 2023-07, Vol.42 (14), p.e112614-n/a
Hauptverfasser: Yamazaki, Masaya, Hino, Shinjiro, Usuki, Shingo, Miyazaki, Yoshihiro, Oda, Tatsuya, Nakao, Mitsuyoshi, Ito, Takaaki, Yamagata, Kazuya
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page n/a
container_issue 14
container_start_page e112614
container_title The EMBO journal
container_volume 42
creator Yamazaki, Masaya
Hino, Shinjiro
Usuki, Shingo
Miyazaki, Yoshihiro
Oda, Tatsuya
Nakao, Mitsuyoshi
Ito, Takaaki
Yamagata, Kazuya
description Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability. Synopsis Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC. Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1. Intratumoral ROR1 high cells are tumor‐initiating cells with increased tumorigenic capacity. ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis. ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation. ROR1 transcription is dependent on the YAP/BRD4 axis. Graphical Abstract ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.
doi_str_mv 10.15252/embj.2022112614
format Article
fullrecord <record><control><sourceid>proquest_C6C</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10350825</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2806073657</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS1ERYfCnhWyxIZN2msndlIJCbWlQFFR0QgWrCzHPzMeJXZqJ1Sz6yPwjDwJbqc_FAmxsn39naNzdBF6QWCXMMronunb1S4FSgmhnFSP0IxUHAoKNXuMZpBnRUWa_W30NKUVALCmJk_QdlnDPucNmaHl94Mve4fzd9Wvy58q-DGGrjMaz8_mBA8x9GE0CY9TH2IGnHejk6PzC6xM1yUsvcbL9WBiRjtnTcyfwWPn8SC9iiY_FVb5auIztGVll8zzm3MHfXt__PXoY3F69uHk6OC0UIxCVTRKa5rjt7RWVWlZqSjXwKzlugWpAWxracVLTZglJRjQhjFaU6VlRVQe7aC3G99hanujlcmdZCeG6HoZ1yJIJx7-eLcUi_BDECgZNJRlh9c3DjGcTyaNonfpqq_0JkxJ0AY41CVndUZf_YWuwhR97pepsiF1STlkCjaUiiGlaOxdGgLieo_iao_ifo9Z8vLPFneC28Vl4M0GuHCdWf_XUBx_Pvz0wJ9s5Ckr_cLE--D_zPQbrlK92Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2838173260</pqid></control><display><type>article</type><title>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</title><source>Springer Nature OA Free Journals</source><creator>Yamazaki, Masaya ; Hino, Shinjiro ; Usuki, Shingo ; Miyazaki, Yoshihiro ; Oda, Tatsuya ; Nakao, Mitsuyoshi ; Ito, Takaaki ; Yamagata, Kazuya</creator><creatorcontrib>Yamazaki, Masaya ; Hino, Shinjiro ; Usuki, Shingo ; Miyazaki, Yoshihiro ; Oda, Tatsuya ; Nakao, Mitsuyoshi ; Ito, Takaaki ; Yamagata, Kazuya</creatorcontrib><description>Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability. Synopsis Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC. Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1. Intratumoral ROR1 high cells are tumor‐initiating cells with increased tumorigenic capacity. ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis. ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation. ROR1 transcription is dependent on the YAP/BRD4 axis. Graphical Abstract ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.</description><identifier>ISSN: 0261-4189</identifier><identifier>EISSN: 1460-2075</identifier><identifier>DOI: 10.15252/embj.2022112614</identifier><identifier>PMID: 37096681</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adenocarcinoma ; AKT protein ; AURKB ; Aurora kinase ; BRD4 ; Cancer ; Cancer therapies ; Carcinoma, Pancreatic Ductal - genetics ; Cell Cycle Proteins - metabolism ; Cell Line, Tumor ; Cell Proliferation ; Chemoresistance ; Chemotherapy ; E2F protein ; EMBO03 ; Epithelial-Mesenchymal Transition ; Gene Expression Regulation, Neoplastic ; Gene sequencing ; Humans ; Kinases ; Life Sciences ; Metastases ; Metastasis ; Myc protein ; Nuclear Proteins - metabolism ; pancreatic adenocarcinoma ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - metabolism ; Protein-tyrosine kinase receptors ; Receptor Tyrosine Kinase-like Orphan Receptors - genetics ; Receptor Tyrosine Kinase-like Orphan Receptors - metabolism ; Receptors ; ROR1 ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Tumor cells ; Tumors ; tumor‐initiating cells ; Tyrosine ; Yes-associated protein</subject><ispartof>The EMBO journal, 2023-07, Vol.42 (14), p.e112614-n/a</ispartof><rights>The Author(s) 2023</rights><rights>2023 The Authors</rights><rights>2023 The Authors.</rights><rights>2023 EMBO</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</citedby><cites>FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</cites><orcidid>0000-0002-5748-016X ; 0000-0003-4151-4983 ; 0000-0002-9959-3322 ; 0000-0002-2196-8673 ; 0000-0001-5528-3464 ; 0000-0001-7564-7579</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350825/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350825/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,41096,42165,45550,45551,46384,46808,51551,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://doi.org/10.15252/embj.2022112614$$EView_record_in_Springer_Nature$$FView_record_in_$$GSpringer_Nature</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37096681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yamazaki, Masaya</creatorcontrib><creatorcontrib>Hino, Shinjiro</creatorcontrib><creatorcontrib>Usuki, Shingo</creatorcontrib><creatorcontrib>Miyazaki, Yoshihiro</creatorcontrib><creatorcontrib>Oda, Tatsuya</creatorcontrib><creatorcontrib>Nakao, Mitsuyoshi</creatorcontrib><creatorcontrib>Ito, Takaaki</creatorcontrib><creatorcontrib>Yamagata, Kazuya</creatorcontrib><title>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</title><title>The EMBO journal</title><addtitle>EMBO J</addtitle><addtitle>EMBO J</addtitle><description>Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability. Synopsis Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC. Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1. Intratumoral ROR1 high cells are tumor‐initiating cells with increased tumorigenic capacity. ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis. ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation. ROR1 transcription is dependent on the YAP/BRD4 axis. Graphical Abstract ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.</description><subject>Adenocarcinoma</subject><subject>AKT protein</subject><subject>AURKB</subject><subject>Aurora kinase</subject><subject>BRD4</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Pancreatic Ductal - genetics</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>E2F protein</subject><subject>EMBO03</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Gene sequencing</subject><subject>Humans</subject><subject>Kinases</subject><subject>Life Sciences</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Myc protein</subject><subject>Nuclear Proteins - metabolism</subject><subject>pancreatic adenocarcinoma</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Protein-tyrosine kinase receptors</subject><subject>Receptor Tyrosine Kinase-like Orphan Receptors - genetics</subject><subject>Receptor Tyrosine Kinase-like Orphan Receptors - metabolism</subject><subject>Receptors</subject><subject>ROR1</subject><subject>Transcription Factors - genetics</subject><subject>Transcription Factors - metabolism</subject><subject>Tumor cells</subject><subject>Tumors</subject><subject>tumor‐initiating cells</subject><subject>Tyrosine</subject><subject>Yes-associated protein</subject><issn>0261-4189</issn><issn>1460-2075</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS1ERYfCnhWyxIZN2msndlIJCbWlQFFR0QgWrCzHPzMeJXZqJ1Sz6yPwjDwJbqc_FAmxsn39naNzdBF6QWCXMMronunb1S4FSgmhnFSP0IxUHAoKNXuMZpBnRUWa_W30NKUVALCmJk_QdlnDPucNmaHl94Mve4fzd9Wvy58q-DGGrjMaz8_mBA8x9GE0CY9TH2IGnHejk6PzC6xM1yUsvcbL9WBiRjtnTcyfwWPn8SC9iiY_FVb5auIztGVll8zzm3MHfXt__PXoY3F69uHk6OC0UIxCVTRKa5rjt7RWVWlZqSjXwKzlugWpAWxracVLTZglJRjQhjFaU6VlRVQe7aC3G99hanujlcmdZCeG6HoZ1yJIJx7-eLcUi_BDECgZNJRlh9c3DjGcTyaNonfpqq_0JkxJ0AY41CVndUZf_YWuwhR97pepsiF1STlkCjaUiiGlaOxdGgLieo_iao_ifo9Z8vLPFneC28Vl4M0GuHCdWf_XUBx_Pvz0wJ9s5Ckr_cLE--D_zPQbrlK92Q</recordid><startdate>20230717</startdate><enddate>20230717</enddate><creator>Yamazaki, Masaya</creator><creator>Hino, Shinjiro</creator><creator>Usuki, Shingo</creator><creator>Miyazaki, Yoshihiro</creator><creator>Oda, Tatsuya</creator><creator>Nakao, Mitsuyoshi</creator><creator>Ito, Takaaki</creator><creator>Yamagata, Kazuya</creator><general>Nature Publishing Group UK</general><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5748-016X</orcidid><orcidid>https://orcid.org/0000-0003-4151-4983</orcidid><orcidid>https://orcid.org/0000-0002-9959-3322</orcidid><orcidid>https://orcid.org/0000-0002-2196-8673</orcidid><orcidid>https://orcid.org/0000-0001-5528-3464</orcidid><orcidid>https://orcid.org/0000-0001-7564-7579</orcidid></search><sort><creationdate>20230717</creationdate><title>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</title><author>Yamazaki, Masaya ; Hino, Shinjiro ; Usuki, Shingo ; Miyazaki, Yoshihiro ; Oda, Tatsuya ; Nakao, Mitsuyoshi ; Ito, Takaaki ; Yamagata, Kazuya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5204-8cdd2207b27c43f53c26d05ff6db0ad00fbf2463d15f130e0de55272cda41cf13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenocarcinoma</topic><topic>AKT protein</topic><topic>AURKB</topic><topic>Aurora kinase</topic><topic>BRD4</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Pancreatic Ductal - genetics</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>E2F protein</topic><topic>EMBO03</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Gene sequencing</topic><topic>Humans</topic><topic>Kinases</topic><topic>Life Sciences</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Myc protein</topic><topic>Nuclear Proteins - metabolism</topic><topic>pancreatic adenocarcinoma</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Protein-tyrosine kinase receptors</topic><topic>Receptor Tyrosine Kinase-like Orphan Receptors - genetics</topic><topic>Receptor Tyrosine Kinase-like Orphan Receptors - metabolism</topic><topic>Receptors</topic><topic>ROR1</topic><topic>Transcription Factors - genetics</topic><topic>Transcription Factors - metabolism</topic><topic>Tumor cells</topic><topic>Tumors</topic><topic>tumor‐initiating cells</topic><topic>Tyrosine</topic><topic>Yes-associated protein</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yamazaki, Masaya</creatorcontrib><creatorcontrib>Hino, Shinjiro</creatorcontrib><creatorcontrib>Usuki, Shingo</creatorcontrib><creatorcontrib>Miyazaki, Yoshihiro</creatorcontrib><creatorcontrib>Oda, Tatsuya</creatorcontrib><creatorcontrib>Nakao, Mitsuyoshi</creatorcontrib><creatorcontrib>Ito, Takaaki</creatorcontrib><creatorcontrib>Yamagata, Kazuya</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The EMBO journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Yamazaki, Masaya</au><au>Hino, Shinjiro</au><au>Usuki, Shingo</au><au>Miyazaki, Yoshihiro</au><au>Oda, Tatsuya</au><au>Nakao, Mitsuyoshi</au><au>Ito, Takaaki</au><au>Yamagata, Kazuya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer</atitle><jtitle>The EMBO journal</jtitle><stitle>EMBO J</stitle><addtitle>EMBO J</addtitle><date>2023-07-17</date><risdate>2023</risdate><volume>42</volume><issue>14</issue><spage>e112614</spage><epage>n/a</epage><pages>e112614-n/a</pages><issn>0261-4189</issn><eissn>1460-2075</eissn><abstract>Tumor‐initiating cells are major drivers of chemoresistance and attractive targets for cancer therapy, however, their identity in human pancreatic ductal adenocarcinoma (PDAC) and the key molecules underlying their traits remain poorly understood. Here, we show that a cellular subpopulation with partial epithelial‐mesenchymal transition (EMT)‐like signature marked by high expression of receptor tyrosine kinase‐like orphan receptor 1 (ROR1) is the origin of heterogeneous tumor cells in PDAC. We demonstrate that ROR1 depletion suppresses tumor growth, recurrence after chemotherapy, and metastasis. Mechanistically, ROR1 induces the expression of Aurora kinase B (AURKB) by activating E2F through c‐Myc to enhance PDAC proliferation. Furthermore, epigenomic analyses reveal that ROR1 is transcriptionally dependent on YAP/BRD4 binding at the enhancer region, and targeting this pathway reduces ROR1 expression and prevents PDAC growth. Collectively, our findings reveal a critical role for ROR1high cells as tumor‐initiating cells and the functional importance of ROR1 in PDAC progression, thereby highlighting its therapeutic targetability. Synopsis Cancer cell diversity and contribution of tumor‐initiating cells to pancreatic ductal adenocarcinoma (PDAC) progression remain poorly defined. In this work, single‐cell RNA sequencing and functional analyses uncovered targetable tumor‐initiating cells in PDAC. Heterogeneous tumor cells in PDAC arise from a subpopulation with partial EMT signature characterized by high expression of ROR1. Intratumoral ROR1 high cells are tumor‐initiating cells with increased tumorigenic capacity. ROR1 functionally promotes PDAC tumor growth, relapse after chemotherapy, and metastasis. ROR1 induces the expression of AURKB via activation of AKT/c‐Myc/E2F signaling, thereby enhancing PDAC proliferation. ROR1 transcription is dependent on the YAP/BRD4 axis. Graphical Abstract ROR1 marks an aggressive partial EMT cell cluster and enhances PDAC proliferation via c‐Myc/E2F/AURKB signaling.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>37096681</pmid><doi>10.15252/embj.2022112614</doi><tpages>32</tpages><orcidid>https://orcid.org/0000-0002-5748-016X</orcidid><orcidid>https://orcid.org/0000-0003-4151-4983</orcidid><orcidid>https://orcid.org/0000-0002-9959-3322</orcidid><orcidid>https://orcid.org/0000-0002-2196-8673</orcidid><orcidid>https://orcid.org/0000-0001-5528-3464</orcidid><orcidid>https://orcid.org/0000-0001-7564-7579</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 0261-4189
ispartof The EMBO journal, 2023-07, Vol.42 (14), p.e112614-n/a
issn 0261-4189
1460-2075
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10350825
source Springer Nature OA Free Journals
subjects Adenocarcinoma
AKT protein
AURKB
Aurora kinase
BRD4
Cancer
Cancer therapies
Carcinoma, Pancreatic Ductal - genetics
Cell Cycle Proteins - metabolism
Cell Line, Tumor
Cell Proliferation
Chemoresistance
Chemotherapy
E2F protein
EMBO03
Epithelial-Mesenchymal Transition
Gene Expression Regulation, Neoplastic
Gene sequencing
Humans
Kinases
Life Sciences
Metastases
Metastasis
Myc protein
Nuclear Proteins - metabolism
pancreatic adenocarcinoma
Pancreatic cancer
Pancreatic Neoplasms
Pancreatic Neoplasms - metabolism
Protein-tyrosine kinase receptors
Receptor Tyrosine Kinase-like Orphan Receptors - genetics
Receptor Tyrosine Kinase-like Orphan Receptors - metabolism
Receptors
ROR1
Transcription Factors - genetics
Transcription Factors - metabolism
Tumor cells
Tumors
tumor‐initiating cells
Tyrosine
Yes-associated protein
title YAP/BRD4‐controlled ROR1 promotes tumor‐initiating cells and hyperproliferation in pancreatic cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_C6C&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=YAP/BRD4%E2%80%90controlled%20ROR1%20promotes%20tumor%E2%80%90initiating%20cells%20and%20hyperproliferation%20in%20pancreatic%20cancer&rft.jtitle=The%20EMBO%20journal&rft.au=Yamazaki,%20Masaya&rft.date=2023-07-17&rft.volume=42&rft.issue=14&rft.spage=e112614&rft.epage=n/a&rft.pages=e112614-n/a&rft.issn=0261-4189&rft.eissn=1460-2075&rft_id=info:doi/10.15252/embj.2022112614&rft_dat=%3Cproquest_C6C%3E2806073657%3C/proquest_C6C%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2838173260&rft_id=info:pmid/37096681&rfr_iscdi=true